Toni K. Choueiri, MD
AACR-Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research

Toni K. Choueiri, MD

Director, Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute;
Co-Leader, Kidney Cancer Program
Dana-Farber/Harvard Cancer Center;
Jerome and Nancy Kohlberg Professor of Medicine
Harvard Medical School
Boston, MA

For transformative advancements in the treatment of renal cell carcinoma (RCC), thereby significantly extending patient survival rates for those with metastatic and high-risk disease. Dr. Choueiri has led paradigm-shifting clinical trials that resulted in FDA approval of multiple novel therapies, including tyrosine kinase inhibitors, immune checkpoint inhibitors, HIF-2α inhibitors and personalized cancer vaccines in RCC. His translational research has uncovered critical biomarkers of response and toxicity, in turn expanding the understanding of tumor immunogenicity, and informing precision medicine approaches in kidney cancer.

In 2017, the AACR instituted the AACR-Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research to recognize a worthy cancer researcher who has conducted highly meritorious translational and clinical cancer research anywhere in the world, and who has not yet reached 51 years of age at the time of award presentation. The award was established in recognition of the extraordinary contributions that Hong, a Fellow of the AACR Academy, made to advances in cancer research, cancer care, and cancer prevention during his long-standing and brilliant career as a physician-scientist. To learn more, please visit the press release.

View Past Recipients.